Consequently, in heart conditions associated with extensive PARP1 activation and NAD+ depletion, as disclosed here in experimental AF, the pharmacological inhibition of PARP1 may offer substantial therapeutic benefits. Here, PARP1 is linked to atrial fibrillation.